M&A / Deals Roche looks to Astex in $515m breast cancer deal PharmaphorumRoche's Genentech unit has forged an alliance with Astex, worth up to $515m, to partner on a fragment-based drug discovery programme in breast cancer.OncologyRead full story pharminent July 6, 2026 (Last updated: July 7, 2026) Pharmaphorum Roche’s Genentech unit has forged an alliance with Astex, worth up to $515m, to partner on a fragment-based drug discovery programme in breast cancer. Oncology Read full story Post navigation Previous: Wegovy pill launches in UK as first daily oral GLP1 for weight managementNext: Novartis to acquire Myricx Bio in up to $1.5bn deal Related Stories M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026 M&A / Deals Sandoz targets industry patent void with $322m Henlius deal pharminent August 17, 2026 M&A / Deals PTC takes a chance on Sangamo’s Fabry disease gene therapy pharminent August 13, 2026
